In a nutshell This study is evaluating the effectiveness of EPOCH-R chemotherapy for patients with non-Hodgkin's lymphoma (NHL) who are HIV-positive. The main outcome to be measured will be survival without cancer growing or spreading. This study is recruiting in Bethesda, Maryland, United States. The details Patients with NHL who are...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Looking for patients with small lymphocytic lymphoma to test acalabrutinib-obinutuzumab combination
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona, Jacksonville,...
Read MoreEvaluating long-term fatigue in survivors of non-Hodgkin’s lymphoma
In a nutshell This study evaluated long-term fatigue in patients with non-Hodgkin’s lymphoma (NHL). This study concluded that severe fatigue in common after initial treatment in NHL survivors. Some background Survivors of lymphoma often develop late complications, such as side effects that last a long time. About 30% of survivors develop...
Read MoreAn update on treatment options for diffuse B-cell lymphoma
In a nutshell This article reviewed treatment options for patients with diffuse large B-cell lymphoma (DLBCL). Some background DLBCL is one of the most common types of non-Hodgkin's lymphoma (NHL). Chemoimmunotherapy is the typical first-line treatment for patients with NHL. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreEvaluating long-term outcomes for patients with stage 1 NHL
In a nutshell This study investigated the long-term survival outcomes of patients with stage 1 non-Hodgkin’s lymphoma (NHL). This study concluded that these patients have favorable outcomes but may need follow-up after 5 years of remission (no cancer recurrence). Some background Most patients with early-stage (stage 1 – 2) NHL tend to have...
Read MoreEvaluating PCR therapy for previously untreated indolent non-Hodgkin’s lymphoma
In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....
Read MoreLooking for patients with relapse/unresponsive lymphoma to test a treatment combination
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read MoreEvaluating the effects of music during chemotherapy for patients with lymphoma
In a nutshell This study examined whether listening to music during chemotherapy reduces anxiety in patients with newly diagnosed lymphoma. This study concluded that live music reduced anxiety in these patients. Some background During and after chemotherapy treatment, patients with lymphoma may experience severe anxiety. Fearful thoughts about the...
Read MoreDoes donor type and melphalan dose impact outcomes for patients with lymphoma who receive a stem cell transplant?
In a nutshell This study aimed to investigate the impact of donor type and melphalan (Alkeran) dose on transplant outcomes for patients with lymphoma. This study concluded that different donor types and melphalan doses have similar outcomes for these patients. Some background Allogenic hematopoietic stem cell transplant (allo-HSCT) is a potentially...
Read MoreThe impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read MoreCurrent developments in research for mantle cell lymphoma
In a nutshell This article reviewed new developments in treatments and disease management for mantle cell lymphoma (MCL). Some background MCL is an aggressive type of non-Hodgkin’s lymphoma. The typical first-line treatment for MCL is chemoimmunotherapy. The most commonly used regimen is R-CHOP. 80 – 90% of patients respond to this...
Read MoreSearching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.
In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...
Read More
